Completed trials in Bulgaria: Trial Insights

Filters: Status: Completed Country / region: Bulgaria Clear all

2,097 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2000	4
2001	8
2002	7
2003	17
2004	35
2005	51
2006	70
2007	69
2008	87
2009	93
2010	100
2011	133
2012	126
2013	120
2014	134
2015	153
2016	134
2017	117
2018	109
2019	112
2020	106
2021	88
2022	94
2023	67
2024	46
2025	13
2026	1

Trials by status
Category	Trials
Completed	2,097

Top lead sponsors
Category	Trials
AstraZeneca	146
Novartis Pharmaceuticals	107
Hoffmann-La Roche	105
Pfizer	85
GlaxoSmithKline	80
Bayer	73
Novo Nordisk A/S	59
Sanofi	54
Janssen Research & Development, LLC	50
Boehringer Ingelheim	46

Top conditions
Category	Trials
Arthritis, Rheumatoid	116
Diabetes Mellitus, Type 2	96
Asthma	82
Pulmonary Disease, Chronic Obstructive	81
Schizophrenia	58
Breast Neoplasms	51
Colitis, Ulcerative	43
Diabetes Mellitus	43
Major Depressive Disorder	43
Renal Insufficiency, Chronic	43

Trials

Showing 76 to 100 of 2,097. Each trial links to its page on Pharma Observatory.

A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis NCT06073119Phase 2CompletedSanofiStarted 2023
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age NCT06087640Phase 3CompletedSeqirusStarted 2023
A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants NCT06068855Phase 3CompletedAbbVieStarted 2023
SBD121, a Synbiotic Medical Food for RA Management NCT06005220Not applicableCompletedSolarea Bio, IncStarted 2023
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer NCT05848011Phase 2CompletedMacroGenicsStarted 2023
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor NCT06065540Phase 3CompletedNovo Nordisk A/SStarted 2023
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA® NCT06037590Phase 1CompletedPureIMS B.V.Started 2023
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations NCT06040086Phase 3CompletedAstraZenecaStarted 2023
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus NCT06013995Phase 1CompletedBristol-Myers SquibbStarted 2023
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma NCT05668390Phase 3CompletedStallergenes GreerStarted 2023
A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric) NCT05915026Phase 3CompletedBayerStarted 2023
Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms. NCT05931861Not applicableCompletedLaboratoires TheaStarted 2023
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age NCT05856227Phase 3CompletedBasilea PharmaceuticaStarted 2023
EXOMIND (BTL-995) for Reduction of Binge-eating NCT06910592Not applicableCompletedBTL Industries Ltd.Started 2023
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) NCT05798520Phase 2CompletedBiogenStarted 2023
Pharmacokinetic Parameters of Stiripentol in Renal Impaired Patients and Matching Controls With Normal Renal Function NCT05735951Phase 1CompletedBiocodexStarted 2023
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems NCT05915702Phase 3CompletedBayerStarted 2023
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) NCT05915728Phase 3CompletedBayerStarted 2023
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus NCT05856448Phase 2CompletedLakefront Biotherapeutics NVStarted 2023
Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections NCT05599295Phase 2CompletedMelinta Therapeutics, LLCStarted 2023
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis NCT05814627Phase 3CompletedAbbVieStarted 2023
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia NCT05852431Phase 3Completed89bio, Inc.Started 2023
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) NCT05764161Phase 3CompletedIncyte CorporationStarted 2023
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis NCT05507580Phase 4CompletedAbbVieStarted 2023
A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants NCT05618808Phase 2CompletedRegeneron PharmaceuticalsStarted 2023

1,997 more trials match. See them on Pharma Observatory

Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients NCT06551064Completion date change2026-06-30 to 2026-07-07October 22, 2026
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis NCT03989206Enrollment change1700 to 1935October 22, 2026
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients NCT06551064Status changeActive, not recruiting to CompletedOctober 22, 2026
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis NCT03989206Status changeActive, not recruiting to CompletedOctober 22, 2026
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment NCT06750289Completion date change2028-11-03 to 2026-09-21October 18, 2026
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment NCT06750289Enrollment change400 to 130October 18, 2026
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment NCT06750289Status changeRecruiting to CompletedOctober 18, 2026
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC NCT05611671Completion date change2026-08-31 to 2026-09-21October 17, 2026
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC NCT05611671Status changeActive, not recruiting to CompletedOctober 17, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory